Stockscreener 앱 받기
74.96
3.20%
2.325
시간 외 거래:
75.09
0.13
+0.17%
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Price to sales forward of Halozyme Therapeutics, Inc. – FWB:RV7 - TradingView
Price to sales forward of Halozyme Therapeutics, Inc. – BMV:HALO - TradingView
Halozyme Therapeutics, Inc. Actuals & Estimates (NASDAQ:HALO) - TradingView
Halozyme Therapeutics, Inc. Actuals & Estimates (DUS:RV7) - TradingView
Halozyme Therapeutics Inc (HALO) Institutional Confidence - TradingKey
Halozyme Therapeutics, Inc. Actuals & Estimates (FWB:RV7) - TradingView
HALO Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO - TradingView
RV7 Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO - TradingView
Enterprise value to revenue forward of Halozyme Therapeutics, Inc. – TRADEGATE:RV7 - TradingView
Price to earnings forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO - TradingView
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection - GlobeNewswire Inc.
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Exploring a 22% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews
Halozyme Therapeutics Inc (HALO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
META_TITLE_QUOTE - Yahoo Finance
Did Expanding ENHANZE Partnerships and Cash Generation Just Shift Halozyme Therapeutics' (HALO) Investment Narrative? - Sahm
HALOZYME THERAPEUTICS INC (HALO) Stock Chart - ChartMill
Halozyme Therapeutics Inc (HALO) Valuation: PE, PB & Fair Value Analysis - TradingKey
What Halozyme Therapeutics (HALO)'s New ENHANZE Partner Data and Analyst Support Means For Shareholders - Sahm
Halozyme Therapeutics (HALO) Stock Could Be 18.8% Undervalued As Partner Growth Lifts Sentiment - Sahm
Halozyme Therapeutics Inc (HALO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Halozyme Therapeutics Inc (HALO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Halozyme Therapeutics Inc (HALO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Halozyme Therapeutics Inc (HALO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Halozyme Therapeutics Inc (HALO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO) - The Globe and Mail
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $95 - Moomoo
Halozyme (HALO) CLO reports RSU vesting and share withholding for taxes - Stock Titan
Goldman Sachs Maintains Halozyme Therapeutics(HALO.US) With Sell Rating, Raises Target Price to $57 - Moomoo
Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $93 - Moomoo
(HALO) Volatility Zones as Tactical Triggers - Stock Traders Daily
Halozyme Therapeutics Expects Proposed Rule to Have Little Impact on Royalties - marketscreener.com
Halozyme sees minimal impact from Medicare drug pricing rule - Investing.com
Halozyme sees minimal impact from Medicare drug pricing rule By Investing.com - Investing.com Australia
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029 - PR Newswire
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Biotech Powerhouse with a 20% Upside Potential - DirectorsTalk Interviews
Halozyme Therapeutics (HALO) up 0.8% since last earnings report: Can it continue? - MSN
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance Singapore
Halozyme Therapeutics (HALO) CFO files Form 3 insider ownership statement - Stock Titan
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Uncovering a 17.29% Potential Upside with Strong Revenue Growth - DirectorsTalk Interviews
Natixis Advisors LLC Has $6.68 Million Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Quick ratio of Halozyme Therapeutics, Inc. – XETR:RV7 - TradingView
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Data And Analyst Buy Reaffirmation - Sahm
ETFs Investing in Halozyme Therapeutics, Inc. Stocks - TradingView
Halozyme Therapeutics, Inc. Income Statement – XETR:RV7 - TradingView
TD Asset Management Inc Lowers Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme licenses Hypercon technology to Oruka for psoriasis drug - Investing.com
Halozyme Therapeutics (HALO) Gains 2.76% as Shares Approach Key ResistanceMA Crossover - newsline.com
How New ENHANZE Data And Analyst Support At Halozyme Therapeutics (HALO) Has Changed Its Investment Story - Yahoo Finance
Halozyme Therapeutics(HALO.US) Officer Sells US$3.37 Million in Common Stock - Moomoo
Halozyme CEO Helen Torley sells $3.37m in shares after exercising options By Investing.com - Investing.com South Africa
Halozyme Therapeutics Stock Gains 5.2% on Analyst Buy Rating and argenx Data NewsNews and Statistics - IndexBox
Halozyme CEO Helen Torley sells $3.37m in shares after exercising options - Investing.com
Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today - Yahoo Finance
Halozyme (NASDAQ: HALO) CEO sells 50K shares after exercising 50K options - Stock Titan
Halozyme Therapeutics (NASDAQ:HALO) Trading Up 5.6%Here's What Happened - MarketBeat
Halozyme Therapeutics Jumps 5.4% Amid Sector-Wide Rally - AlphaStreet
Benchmark reiterates Halozyme stock Buy rating on long-term potential - Investing.com
Benchmark reiterates Halozyme stock Buy rating on long-term potential By Investing.com - Investing.com Canada
Halozyme Therapeutics Inc (NASDAQ:HALO): A Deep Value Play Combining Strong Profitability with an Attractive 14.35 P/E - ChartMill
Insider Sell Alert: Bernadette Connaughton Sells Shares of Haloz - GuruFocus
1.36%
자본화:
|
볼륨(24시간):